Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prostatectomy After Conversion Therapy in High-volume mHSPC
NCT07268794Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Fudan University. Primary endpoint: Radiographic Progression-free Survival at 24 months. Planned start Nov 2025; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07268794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268794.